Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Levitee Labs in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Levitee Labs. This N/A consensus rating has held steady for over two years.
Levitee Labs Inc., a multidisciplinary integrative wellness company, provides evidence-based alternative medicines and novel psychedelic therapies. The company operates through two segments, Medical Services and Selling Products. It offers treatments and medications for substance use disorders and chronic pain, such as myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome, as well as hepatitis-C and mental health conditions. The company operates five clinics under the Levitee Clinics name; and three pharmacies in Alberta under the Levitee Pharmacies name. In addition, it offers electronic-prescriptions in the addiction treatment space under the BlockMD name; and wholesales supplements and superfood under the Earth Circle Organics name. The company was formerly known as Fibonacci Capital Corp. and changed its name to Levitee Labs Inc. in November 30, 2020. Levitee Labs Inc. was incorporated in 2019 and is based in Vancouver, Canada.
Read More
